May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Safety and Efficacy of Intravitreal Ranibizumab (Lucentis) for the Treatment of Macular Edema Not Secondary to Age-Related Macular Degeneration
Author Affiliations & Notes
  • R. A. Sisk
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • N. Z. Gregori
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    Ophthalmology, Miami Veterans Affairs Medical Center, Miami, Florida
  • Footnotes
    Commercial Relationships  R.A. Sisk, None; N.Z. Gregori, Eyetech, C.
  • Footnotes
    Support  NIH Grant P30 EY14801
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2684. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. A. Sisk, N. Z. Gregori; Safety and Efficacy of Intravitreal Ranibizumab (Lucentis) for the Treatment of Macular Edema Not Secondary to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2684. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the safety and efficacy of off-label intravitreal ranibizumab (Lucentis®, Genentech) for the treatment of macular edema (ME) from causes other than exudative age-related macular degeneration (AMD). Secondly, to determine if different etiologies of macular edema respond more or less favorably to anti-vascular endothelial growth factor (VEGF) therapy.

Methods: : Retrospective consecutive noncomparative case series. A chart review was performed of all eyes treated with intravitreal ranibizumab for ME secondary to any non-AMD etiology at the Miami Veterans Affairs Medical Center between October 31, 2006 and October 31, 2007. All patients underwent routine Snellen visual acuity (VA) assessment and Stratus OCT (Carl Zeiss Meditech, Inc.) imaging with 1 mm central retinal thickness measurements as part of their routine clinical care. The dose of ranibizumab was 0.5 mg (0.05 ml). Retreatment was performed at monthly or longer intervals at the discretion of the treating physician.

Results: : 48 consecutive patients were treated with intravitreal ranibizumab for ME due to diffuse diabetic macular edema (24), branch retinal vein occlusion (8), central retinal vein occlusion (9), Irvine-Gass syndrome (6), and idiopathic macular telangiectasia (1). Improvement in VA and OCT central retinal thickness measurements was observed in each group of patients. Overall, central retinal thickness measurements by OCT improved to a greater degree than VA.

Conclusions: : Retinal vein occlusion patients demonstrated the best response to ranibizumab compared to other groups of patients suggesting that venous occlusive disease is mostly a VEGF-driven process and other pro-inflammatory mediators might be more important in diabetes and post-surgical inflammation.

Keywords: macula/fovea • edema • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×